Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
(d)
On April14, 2018, our Board of Directors (the “Board”) appointed Kathryn J. Collier to the Board, to serve until our next annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. Concurrently with her appointment to the Board, the Compensation Committee of the Board determined that Ms.Collier is an “Eligible Director” as that term is defined in our Non-Employee Director Compensation Policy, attached as Exhibit 10.4 to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March3, 2017. Accordingly, on April16, 2018, Ms.Collier became a participant in our Non-Employee Director Compensation Policy and received an automatic grant under our 2012 Equity Incentive Plan (the “Plan”) of an option to purchase up to 110,000 shares of our common stock at an exercise price of $0.64 per share. One-third of the shares subject to the option vest on the one-year anniversary of the date of grant and the balance of shares subject to the option vest in a series of 24 equal monthly installments thereafter, subject to the terms of the Plan. Ms.Collier has also entered into our standard form of indemnification agreement, the form of which is attached as Exhibit 10.1 to our Registration Statement on Form S-1, as amended (File No.333-183384), originally filed with the SEC on August17, 2012.
Concurrently with her appointment to the Board, Ms.Collier was also appointed to serve on the Audit Committee and the Nominating& Corporate Governance Committee of the Board.
About Regulus Therapeutics Inc. (NASDAQ:RGLS)
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
